Article

MRI Successfully Gauges RA Treatment Response

MRI proves itself as a valuable tool for pinpointing inflammatory and structural damage in select rheumatoid arthritis patients.

Peterfy C, Emery P, Tak PP, et al.MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomized, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2014: doi:10.1136/annrheumdis-2014-206015.

MRI may finally be coming into its own for the evaluation of cartilage loss in rheumatoid arthritis (RA). The modality shows rituximab's success in significantly reducing erosion and cartilage loss in RA patients who don't do well on methotrextrate.

This study is the first to demonstrate MRI's ability to reveal cartilage loss, and may give the modality an edge over x-ray in clinical trials for RA treatment response assessment, the authors explain.

MRI allows for direct evaluation of cartilage loss, whereas radiography evaluates cartilage loss indirectly by looking at joint space narrowing, they explain.

They randomized patients to two infusions with rituximab (500 mg or 1,000 mg) or placebo. The patient's affected hand and wrist underwent MRI evaluation at multiple time points.

The authors report that patients assigned to either the 1,000-mg or 500-mg dose have significantly better RAMRIS (Outcome Measures in Rheumatology Clinical Trials RA MRI Scoring) erosion scores versus placebo patients.

MRI proves itself as a valuable tool “for assessing inflammatory and structural damage in patients with established rheumatoid arthritis receiving rituximab, the authors state.

Their conclusion jibes with recommendations from rheumatology societies that support the use of MRI for detecting joint inflammation and assessing treatment response.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.